Navigation Links
U.S. Food and Drug Administration Extends Review Timeline for BRILINTA (Ticagrelor) New Drug Application
Date:9/15/2010

WILMINGTON, Del., Sept. 15 /PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for ticagrelor (BRILINTA).

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO)

Accordingly, the FDA extended the Prescription Drug User Fee Act (PDUFA) date from September 16, 2010 to December 16, 2010. AstraZeneca will continue to work closely with the FDA to support the review of the ticagrelor NDA.

Ticagrelor is currently under regulatory review in nine additional territories around the world, including the European Union, Canada, and Brazil.

NOTES TO EDITORS:

ABOUT BRILINTA/BRILIQUE

Ticagrelor (BRILINTA/BRILIQUE) is an investigational oral antiplatelet treatment for Acute Coronary Syndromes (ACS). Ticagrelor is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Ticagrelor is the first reversibly-binding oral ADP receptor antagonist.

BRILINTA and BRILIQUE are trademarks of the AstraZeneca group of companies.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion dollar healthcare business.

For more information about AstraZeneca in the US or the AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).


'/>"/>
SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market
2. Americans to U.S. Food and Drug Administration: Preserve Life-Saving Medicines; Reduce Antibiotic Use in Food Animal Production
3. Veterans Administration Health Care System Purchases 15 Zargis Cardioscan Systems
4. American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
5. Sperian Respiratory Protection USA Awarded a 65,000 Reusable Respirator Order by the Veterans Health Administration
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Kun Run Biotechnology Announces That They Have Obtained the Manufacturing Approval for Entecavir from the China State Food and Drug Administration
8. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
9. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
10. Federal Aviation Administration Selects Partners For Nationwide AED Program
11. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
(Date:5/26/2016)... ALBANY, New York , May 26, 2016 ... Transparency Market Research "Medical Waste Management Market - U.S. Industry ... the medical waste management market in the U.S. was valued ... expand at a CAGR of 3.4% from 2015 to 2023 ... report provides exhaustive analysis of current and emerging needle free ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/30/2016)... ... 30, 2016 , ... Shaolin Institute officially starts the annual ... intensive summer training camp starts on June 17th on Shaolin Institute Atlanta Campus. ... a fun and unique experience with an opportunity to learn KungFu martial arts ...
(Date:5/28/2016)... (PRWEB) , ... May 28, 2016 , ... SuperCloset is ... all too well the day to day issues, struggles and obstacles veterans’ need to ... Helping Veterans Grow Project provides active or retired military veteran(s) with a donated SuperCloset ...
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of American adults ... that bariatric surgery has received increased attention in recent years, as an article ... comes to weight loss, most people are familiar with the basic requirements of maintaining ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
Breaking Medicine News(10 mins):